Stock Price

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

As BNB Plus Corp. falls from Nasdaq to the over-the-counter markets, its hybrid crypto-biotech model is under intense scrutiny. What does this mean for investors?

ProCap Financial's AI agent has amassed $50B in user assets, signaling a new era for investors. But beyond the hype, what are the real gains and risks?

Amid key technical wins like piloted transition, Vertical Aerospace delays its eVTOL certification, a move reflecting an industry-wide reality check.

With Aon's Q2 results imminent, investors are watching key metrics, strategic moves, and how the firm navigates a complex global risk landscape.

The Real Brokerage's bold merger with RE/MAX creates a new industry titan. But can an AI-driven, cloud-based culture truly integrate with a global franchise empire?

Beyond just a new logo, Chicago Rivet & Machine Co.'s rebrand signals a strategic shift from parts supplier to a systems expert for the next century.

With a historic $26.5B NASDAQ listing, SK hynix solidifies its crucial role in the AI supply chain, escalating the high-stakes race for memory dominance.

JZR Gold secured CAD$1M just as it seizes direct control of its Brazilian mill. Is this the final piece of the puzzle for production, or a dilutive lifeline?

Chinese manufacturer Hongli Group is on the clock to avoid Nasdaq delisting. The path to compliance is fraught with new risks and systemic challenges.

The health-tech acquirer shores up its balance sheet with a $2.3M financing and debt deal, but a heavy reliance on insider transactions raises governance questions.

Fintech firm Lion Group Holding announces a 1-for-9 reverse ADS split to boost its low stock price, a critical move as it pivots toward digital assets.

A securities lawsuit against Peabody Energy and its top brass tests executive accountability after a flagship mine project faltered, costing investors dearly.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

SRX Global's plan to buy back up to 50% of its shares is more than a financial maneuver; it's a bold declaration of faith in its AI-driven model.

A hostile bid for medical device maker InMode has ignited a firestorm, with a major shareholder accusing the CEO of manipulation, self-dealing, and betrayal.

Vera Therapeutics just secured its first drug approval. Now, it's bringing in a regulatory heavyweight. We deconstruct the strategy behind the move.

A new lawsuit alleges Microsoft's "best-in-class" AI was a facade, concealing deep-rooted flaws in Copilot that misled investors and hit its bottom line.

Monster's 2-for-1 split isn't just a technicality. It's a signal of confidence backed by record sales, diversification, and a strategy to fuel growth.

With its stock lagging, Vermilion Energy renews a major share buyback, a defiant signal of undervaluation. Is this a savvy capital play or a bet against market headwinds?